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Introduction {#s1}
============

Inorganic arsenic in water and food is a top priority toxicant for risk assessment and exposure reduction/mitigation ([@c4]; [@c115]) as chronic arsenic exposure affects multiple organ systems, resulting in various cancers and cardiovascular disease, and possibly also in respiratory disease, diabetes, neurocognitive outcomes, and kidney disease ([@c52]; [@c67]; [@c76]; [@c71]; [@c95]; [@c111]). Understanding the health effects of arsenic requires assessing the role of interindividual variation in inorganic arsenic metabolism. After absorption, inorganic arsenic (iAs including arsenate and arsenite) is mainly methylated into monomethylated and dimethylated compounds (MMA, DMA) in the liver, which are then excreted through the kidney together with unmethylated inorganic arsenic ([@c97]). Whether the methylation process is to detoxify or potentiate arsenic toxicity, however, remains an ongoing debate and may depend on the study outcome ([@c84]; [@c92]).

Arsenic metabolism in urine is generally reported as the percentage of each arsenic species divided by their sum (iAs%, MMA%, and DMA%) and/or as the primary and secondary methylation indices (PMI, the ratio of MMA over iAs; and SMI, the ratio of DMA over MMA) ([@c24]). The relative proportion of arsenic metabolites in urine has been reported to be around 10--30% inorganic arsenic, 10--20% MMA, and 60--80% DMA, with substantial interpopulation and intrapopulation variations ([@c37]; [@c44]; [@c87]; [@c96]). Higher levels of MMA% and lower levels of DMA% have been related to cancer and cardiovascular outcomes in populations from Taiwan, Bangladesh, and Argentina ([@c11]; [@c41]; [@c86]; [@c94]). Lower levels of MMA% and higher levels of DMA%, on the other hand, have been related to higher body mass index and diabetes-related outcomes in populations from Mexico, Taiwan, and the United States ([@c9]; [@c34]; [@c35]).

The available evidence on the role of arsenic metabolism in individual susceptibility to the development of cancer, cardiovascular disease, and diabetes has not been formally and comprehensively reviewed. Our objective was to conduct a systematic review to examine the role of arsenic metabolism, as measured in urine, in the development of cancer, cardiovascular disease, and diabetes-related outcomes. We evaluated whether the methylation patterns associated with higher risk of disease are consistent across diseases and across populations with varying arsenic exposure levels. In a secondary analysis, we characterized the urine arsenic metabolism profile in populations around the world.

Methods {#s2}
=======

Search Strategy and Study Selection {#s2.1}
-----------------------------------

The systematic search and review processes were conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines ([@c91]). We searched PubMed/Medline (<https://www.ncbi.nlm.nih.gov/pubmed>) and EMBASE (<https://www.embase.com/>) for original epidemiologic studies investigating the role of arsenic metabolism in the risk of cancer, cardiovascular disease, and diabetes-related outcomes. For arsenic metabolism, we used the following MeSH terms and free text: "arsenic," "methylation," "metabolism," "arsenic metabolism," "arsenic methylation," combined with other specific text-word terms related to the key research concepts. The PubMed and EMBASE database search strategies in the supplementary material \["PubMed and EMBASE database search strategies for arsenic metabolism and outcomes of interest Medline/PubMed (Jan 25, 2016)" and "EMBASE (Jan 25, 2016)"\] show the full search strategy, and Figure S1 shows the flow diagram of study identification, selection, and exclusion. The search period was January 1966 through January 2016. There were no language restrictions. We also manually reviewed the reference lists from relevant original research and the investigators' files.

Our primary exclusion criteria to screen records, after removing studies in nonhuman populations, were as follows: *a*) publications contained no original research (i.e., reviews, editorials, nonresearch letters); *b*) case reports and case series; *c*) studies did not measure cancer, cardiovascular outcomes (coronary heart disease, stroke, peripheral arterial disease, and hypertension), or diabetes and diabetes-related outcomes (including prediabetes and metabolic syndrome); and *d*) studies did not report information on arsenic metabolism, as measured by urine (percentage or ratios of urine arsenic species). After full text review, records were excluded if they met any of the following conditions: *a*) lacked report of the association between arsenic metabolism and the study outcome; *b*) focused only on arsenic-related skin lesions (premalignancy); *c*) were conducted among pregnant women (pregnancy may influence arsenic metabolism) ([@c38]), or *d*) were conducted among those less than 18 y of age([@c93]). Several studies that measured arsenic metabolism were excluded because they only reported the association for arsenic exposure with study outcomes stratified by arsenic metabolism levels, but not for arsenic metabolism per se ([@c30]; [@c54]; [@c94]). For studies conducted in the same study population and with same outcome of interest \[11 studies from the same population in Taipei ([@c15]; [@c17], [@c21], [@c20], [@c22], [@c18], [@c19]; [@c42]; [@c82]; [@c107]; [@c108]), 2 studies from the same population in Tainan ([@c12], [@c13]), and three studies in the endemic Blackfoot disease area ([@c40]; [@c43], [@c45]), all of above from Taiwan; four studies in Bangladesh ([@c10], [@c11]; [@c109], [@c110]); two studies in Inner Mongolia ([@c55], [@c57])\], we selected the publication with the largest sample size and with more complete information for the final statistical analysis ([@c11], [@c12]; [@c43]; [@c55]; [@c82]).

Data Abstraction {#s2.2}
----------------

Two authors, C.-C.K. and K.A.M., independently abstracted data from articles that met the selection criteria. We used a standardized data extraction form to record the study characteristics (authors, journal, year of publication, country, study design, and study objectives); the participant characteristics \[study population (general vs. hospital-based), number of participants, age, sex, and arsenic exposure levels as measured in urine or water\]; measures of arsenic metabolism (iAs%, MMA%, DMA%, PMI, and SMI); outcome definitions; and the results of the association analysis, including the variables used for adjustment. To assess study quality, we adapted the criteria used by Longnecker et al. for observational studies (see Tables S1--S3) including the domains related to exposure assessment, outcome definition, and modeling approaches ([@c116]). Disagreement between the two reviewers was resolved by consensus and discussion with a third reviewer if needed.

Statistical Methods {#s2.3}
-------------------

For mean age and sex distribution, mean arsenic concentrations in water or urine, and for each arsenic metabolism biomarker (iAs%, MMA%, DMA%, PMI, and SMI), we derived the numbers when not directly reported. For four studies included in the evaluation of metabolism distribution across populations that did not report arsenic concentrations in water or urine, the exposure level was imputed based on reported arsenic levels in water \[$50\;\mu g/L$ in Argentina and in California/Nevada in the United States ([@c86]), $100\;\mu g/L$ in China ([@c55]), and $100\;\mu g/L$ in Northern Chile ([@c65])\] assuming that arsenic levels in urine and water are positively associated ([@c70]). Throughout the study, the estimated arsenic exposure level (eAs, $\mu g/L$) was defined by derived arsenic concentrations in water ($\mu g/L$), urine ($\mu g/L$ or $\mu g/g$ creatinine), or previous biomonitoring data indicating arsenic concentrations in water ($\mu g/L$) relevant at the time of study recruitment. Most studies reported means of arsenic metabolism biomarkers in the population. For studies that did not, we calculated the means of each arsenic metabolism biomarker by dividing the mean concentrations of each arsenic species by the mean of total arsenic or the sum of inorganic and methylated arsenic. For three studies that provided medians of arsenic metabolism biomarkers among cases and noncases, we used the data from noncases to approximate the means of arsenic metabolism biomarkers ([@c33]; [@c43]; [@c60]).

To describe arsenic metabolism across populations, we reported the median (interquartile range) of means in each study for each arsenic metabolism biomarker (iAs%, MMA%, and DMA%). The interpretation of these biomarkers is complicated because they are interdependent and their sum equals 100%. Higher MMA%, for example, could indicate either lower iAs% or lower DMA%. We used a three-axis diagram (triplot, or ternary plot) to represent the means of iAs%, MMA%, and DMA% across study populations. This inherent non-normality of the data makes the conventional linear regression modeling not feasible. We described the relationship between mean arsenic concentrations in urine (among studies without reported urine arsenic levels, concurrent measurements of arsenic levels in drinking water, or published arsenic biomonitoring data were used) and arsenic metabolism biomarkers (iAs%, MMA%, and DMA%) using the isometric log-ratio approach to compositional data analysis ([@c100]). Essentially, we used log-ratio transformations of the arsenic metabolism components in order to apply standard multivariate regression techniques, and we estimated predicted values of each arsenic metabolism component by estimated arsenic exposure. A key principal of this method is scale invariance, meaning that only the relative, not absolute, magnitude of the components is important. Applying the log-ratio methodology with zero or missing values requires additional assumptions ([@c102]). For further information on compositional data analysis, including model diagnostics and variable selection, we refer the reader to the available textbooks and reviews ([@c3]; [@c61]; [@c79]; [@c77]; [@c100]). All statistical analyses and graphical displays for compositional data analysis were performed using packages ggtern (extension of ggplot2 for the creation of tertiary diagrams; Nicholas Hamilton) and compositions: Compositional Data Analysis (version 1.30-1; K. G. van den Boogaart, Raimon Tolosana, Matevz Bren) in R (version 3.0.0; R Development Core Team).

To evaluate the association between arsenic metabolism biomarkers and health effects (cancer, cardiovascular disease and diabetes-related outcomes), we retrieved the relative risk estimates from the model adjusted for the most covariates. There were no large differences between the fully adjusted and crude models. To identify patterns across studies, we assessed the magnitude and direction of the association across studies without taking into account statistical significance but describing whether the individual studies were statistically significant or not. We did not perform a meta-analysis due to the small number of studies for most health endpoints evaluated and inconsistencies in the reporting format across studies.

Results {#s3}
=======

Arsenic Metabolism across Study Populations {#s3.1}
-------------------------------------------

Twenty-six studies met the inclusion criteria, including 12 on cancer, 10 on cardiovascular diseases, and 5 on diabetes-related outcomes. Twelve studies were conducted in Taiwan ([@c9], [@c12], [@c14]; [@c16]; [@c41]; [@c46], [@c43]; [@c47]; [@c82]; [@c104]; [@c112]; [@c113]), four in the United States ([@c33]; [@c51]; [@c68]; [@c86]), three in Bangladesh ([@c10], [@c11]; [@c75]), three in Mexico ([@c23]; [@c60]; [@c66]), 2 in China ([@c55], [@c56]), two in Argentina ([@c86], [@c88]), and one in Chile ([@c65]). The medians (interquartile range) for mean iAs%, MMA%, and DMA% of the 14 unique populations included were 9.4 (7.4--10.2)%, 12.9 (10.1--13.3)%, and 77.3 (71.3--80.1)%, respectively. The compositional means for iAs%, MMA%, and DMA% were 9.4%, 12.3%, and 78.4%, respectively. The distribution and variability of arsenic metabolism across study populations are summarized in [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}, upper panel. Compared with iAs% and DMA%, MMA% showed lower interpopulation variance, with population means ranging from 9.4% in Faridpur, Bangladesh ([@c75]) to 14.6% in Cordoba, Argentina ([@c86]) ([Figure 2](#f2){ref-type="fig"}, upper and middle panel). In an analysis of the relationship between arsenic exposure levels and arsenic metabolism biomarkers, a 2-fold increase in the estimated urine arsenic concentrations was associated with a 0.8% \[95% confidence interval (CI): $- 0.2$, 1.9\] increase in iAs%, no association with MMA% (0.1% increase, 95% CI: $- 0.5$, 0.8), and a 1.3% (95% CI: $- 3.0$, 0.5) decrease in DMA%. In compositional data analysis, we confirmed a similar relationship between arsenic exposure levels and arsenic metabolism indicators at the population level ([Figure 2](#f2){ref-type="fig"}, bottom panel). We conducted sensitivity analyses removing studies with urine arsenic concentrations estimated from imputed water arsenic levels ([@c55]; [@c65]; [@c86]), with similar results: a 2-fold increase in the estimated urine arsenic concentrations was associated with a 0.9% (95% CI: $- 0.1$, 1.9) increase in iAs%, no association with MMA% (0.1% increase, 95% CI: $- 0.6$, 0.8), and a 1.2% (95% CI: $- 3.0$, 0.6) decrease in DMA% (also see Figure S2).

![The distribution of urine arsenic metabolism profile across enrolled populations worldwide on ternery plot diagram. Three-axis graph (triplot) representing the compositional mean of arsenic metabolism biomarkers (iAs%, MMA%, and DMA%) in different study populations. The circles represent each study population and the country of the study is indicated with an acronym (AR, Argentina; BD, Bangladesh; CL, Chile; CN, China; MX, Mexico; TW, Taiwan; US, USA). The size of the circle corresponds to the study population size. The color of the circles reflects the estimated urine arsenic concentrations (eAs, $\mu g/L$) as indicated in the top left legend (the highest two countries: BD and CN; while the lowest two: US and MX. For exact ranking of eAs, please refer to the top panel of Figure 2). The bottom side of the triplot represents iAs%, the right side represents MMA%, and the left side represents DMA%. For each population, the mean iAs%, MMA%, and DMA% can be estimated along parallel lines to the dashed green lines for iAs%, dashed red lines for MMA% and dashed blue lines for DMA%. For instance for the study from Chile (CL), the arsenic metabolism profile was 9.6% for iAs%, 10.8% for MMA% and 79.6% for DMA%. In this graph, we can observe that population means ranged between 5.9% and 16.1% for iAs%, between 9.4 and 14.6% for MMA%, and between 69.3% and 84.2% for DMA%.](EHP577_f1){#f1}

![Variability of arsenic metabolism biomarkers in the study populations. Top panel: The distribution of each arsenic metabolism biomarker (iAs%, MMA%, DMA%) is plotted for each study listed in increasing order (from bottom to top) of the estimated urine arsenic levels in (eAs, $\mu g/L$) in the study area. Middle panel, violin plot showing the median (open circle) with interquartile range (horizontal bar) and the kernel probability density for each arsenic metabolism biomarker (iAs%, MMA%, DMA%) across all studies. Bottom panel, the prediction curve (line) (right for iAs%, central for MMA%, and left for DMA%) derived from the compositional regression of each arsenic metabolism biomarker based on estimated urine arsenic levels (eAs, $\mu g/L$). The right increasing curve supports that iAs% increases as eAs increases and the left decreasing curve supports that DMA% decreases as eAs increases. The central curve supports that MMA% does not change with changes in eAs concentrations as the line is vertical.](EHP577_f2){#f2}

Study Design and Quality Assessment {#s3.2}
-----------------------------------

By study design, seven studies were cross-sectional, 12 were case--control, and seven were prospective cohorts. The studies showed marked heterogeneity in reporting and modeling biomarkers of arsenic metabolism (see Tables S2--S4). Among case--control studies, most of them did not describe the timing of interview, response rate among noncases, and case--control selection, criteria commonly used to address potential surveillance, selection, and recall bias. Prospective studies, on the other hand, generally met important quality criteria, although associations between arsenic metabolism and health outcomes were not adjusted for total arsenic exposure in three studies ([@c16]; [@c41]; [@c104]).

Arsenic Metabolism and Cancer {#s3.3}
-----------------------------

Of the 12 studies on arsenic metabolism and cancer, 2 were prospective cohort studies ([@c16]; [@c43]) and 10 were case--control studies ([Table 1](#t1){ref-type="table"}). Seven studies were conducted in Taiwan, six in the Blackfoot disease endemic area (arsenic in drinking water $\geq 100\;\mu g/L$) ([@c12], [@c14]; [@c16]; [@c41]; [@c43]; [@c113]), and one in Taipei City/County (arsenic in drinking water $< 100\;\mu g/L$) ([@c82]). Outside of Taiwan, the studies were conducted in populations from Argentina ([@c86], [@c88]), Chile ([@c65]), the United States ([@c33]; [@c86]), and Eastern Europe ([@c54]). Study populations from Argentina and Chile were exposed to arsenic levels in drinking water $\geq 100\;\mu g/L$ ([@c65]; [@c86]). The U.S. study populations from California and Nevada were exposed to arsenic levels $> 50\;\mu g/L$ ([@c86]), and the study population from New Hampshire was exposed to arsenic levels in drinking water $< 100\;\mu g/L$ ([@c33]). Five studies evaluated urothelial cancers ([@c14]; [@c43]; [@c65]; [@c82]; [@c86]), four evaluated skin cancer ([@c12]; [@c33]; [@c41]; [@c113]), two evaluated lung cancer ([@c65]; [@c88]), one evaluated breast cancer ([@c60]), and one evaluated all-cancer incidence ([@c16]) ([Table 1](#t1){ref-type="table"}). All studies confirmed incident cancer outcomes using pathological and medical information but did not provide analyses by histological subtypes ([Table 1](#t1){ref-type="table"}). Arsenic metabolism was defined based on the percentages of arsenic metabolites (iAs%, MMA%, and DMA%) in four studies ([@c41]; [@c65]; [@c86]; [@c88]), based on the methylation indices (PMI and SMI) in one study ([@c14]), and based on both the arsenic species proportions and the methylation indices in seven studies ([@c12]; [@c16]; [@c33]; [@c43]; [@c60]; [@c82]; [@c113]) ([Table 1](#t1){ref-type="table"}).

###### 

Studies of arsenic metabolism and cancer.

Table 1 lists the first author and year and the design cases/non case in the first and the second columns, respectively. The population characteristics and the outcomes (ascertainment method) are listed in the third and fourth columns, respectively. The arsenic exposure; the values of iAs%, MMA%, DMA%, PMI, SMI; and adjustment factors are listed in the other columns.

  Reference                            Study design (case/noncase)   Men (%) Age range Source          Outcome (Ascertainment method)                                                   Arsenic exposure                                              Adjustment factors                                                                                                                        
  ------------------------------------ ----------------------------- --------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------- --------------------------- -------------------------- -------------------------- -------------------------- --------------------------------------------------------------------------------------------------------------
  [@c16]                               CO 17/191                     Putai, Taiwan                     All cancer (registry)                                                            Urine (mean total arsenic $78\;\mu g/L$)                      $7.5 \pm 7.5$                $13.0 \pm 8.9$              $79.5 \pm 12.7$            NR                         $9.4 \pm 8.4$              Age, sex, education
  36%                                  $\geq 5.9$ vs. $< 5.9$        $\geq 10.8$ vs. $< 10.8$          $\geq 82.4$ vs $< 82.4$                                                          $\geq 7.4$ vs. $< 7.4$                                                                                                                                                                                  
  Mean 46 y                            0.6 (0.2, 1.7)                2.4 (0.8, 9.1)                    0.9 (0.3, 2.7)                                                                   0.4 (0.1, 1.4)                                                                                                                                                                                          
  General                                                                                                                                                                                                                                                                                                                                                                                       
  [@c14]                               CC 49/224                     Tainan, Taiwan                    Urothelial (pathology)                                                           Water (mean CAE $8.5\;{mg}/L - y$)                            NR                           NR                          NR                         4.8                        10.9                       Age, sex, education, smoking, BMI, hair dye, CAE
  63%                                                                $> 2.7$ vs. $\leq 0.9$            $> 9.4$ vs. $\leq 4.8$                                                                                                                                                                                                                                                                   
  $> 40\; y$                           0.5 (0.2, 1.4)                0.6 (0.3, 1.5)                                                                                                                                                                                                                                                                                                             
  Hospital                                                                                                                                                                                                                                                                                                                                                                                      
  [@c86]                               CC 114/114                    Córdoba, Argentina                Urothelial (pathology)                                                           Water (low-moderate)                                          $16.1 \pm 10.0$              $14.6 \pm 9.7$              $69.3 \pm 16.3$            NR                         NR                         Age, sex, smoking, bombilla use
  82%                                                                NR                                $\geq 16.7$ vs. $< 16.7$                                                         NR                                                                                                                                                                                                      
  20-80 yrs                            1.3 (0.7, 2.4)                                                                                                                                                                                                                                                                                                                                           
  General                                                                                                                                                                                                                                                                                                                                                                                       
  23/49                                California and Nevada, USA    Urothelial carcinoma (registry)   Water (low-moderate)                                                             $11.9 \pm 4.9$                                                $13.2 \pm 4.1$               $74.9 \pm 6.9$              Age, sex, smoking                                                                
  80%                                                                NR                                $\geq 14.9$ vs. $< 14.9$                                                         NR                                                                                                                                                                                                      
  40-85 y                              1.2 (0.4-3.7)                                                                                                                                                                                                                                                                                                                                            
  General                                                                                                                                                                                                                                                                                                                                                                                       
  [@c82]                               CC 177/313                    Taipei, Taiwan                    Urothelial (pathology)                                                           Urine (mean sum iAs, MMA, and DMA $30\;\mu g/g$ creatinine)   $5.9 \pm 6.9$                $9.9 \pm 10.1$              $84.2 \pm 12.6$            $3.3 \pm 11.3$             $12.9 \pm 29.7$            Age, sex, education, alcohol, paternal and maternal ethnicity, pesticide usage
  66%                                                                $> 5.2$ vs. $\leq 2.4$            $> 9.2$ vs. $\leq 3.0$                                                           $> 92.5$ vs. $\leq 85.0$                                      $> 2.0$ vs. $\leq 0.3$       $> 12.7$ vs. $\leq 4.8$                                                                                      
  24-93 y                              1.2 (0.7, 2.0)                2.8 (1.6, 4.8)                    0.4 (0.2, 0.7)                                                                   3.1 (1.7, 5.6)                                                0.3 (0.2, 0.6)                                                                                                                            
  Hospital                             $p - \text{trend} = 0.7$      $p - \text{trend} < 0.0001$       $p - \text{trend} = 0.004$                                                       $p - \text{trend} < 0.001$                                    $p - \text{trend} = 0.001$                                                                                                                
  [@c43]                               CO 37/928                     Putai, Taiwan                     Urothelial                                                                       Urine (median sum iAs, MMA, and DMA $64\;\mu g/L$)            $5.9 \pm \text{median}$      $11.3 \pm \text{median}$    $81.4 \pm \text{median}$   $1.9 \pm \text{median}$    $7.0 \pm \text{median}$    Age, sex, education, smoking, CAE
  43%                                  (registry and pathology)                                        $\geq 8.0$ vs. $< 4.3$                                                           $\geq 15.6$ vs. $< 8.4$                                       $\geq 85.7$ vs. $< 76.0$     $\geq 2.8$ vs. $< 1.3$      $\geq 9.8$ vs. $< 4.8$                                                           
  $> 30\; y$                           1.4 (0.5, 3.6)                1.7 (0.7, 4.0)                    0.3 (0.1, 0.9)                                                                   0.8 (0.4, 2.0)                                                0.5 (0.2, 1.3)                                                                                                                            
  General                              $p - \text{trend} > 0.05$     $p - \text{trend} > 0.05$         $p - \text{trend} < 0.05$                                                        $p - \text{trend} > 0.05$                                     $p - \text{trend} > 0.05$                                                                                                                 
  [@c65]                               CC                            Northern Chile                    Urothelial (medical records)                                                     Water (lifetime average arsenic $109\;\mu g/L$)               $9.6 \pm 6.3$                $10.8 \pm 4.8$              $80.0 \pm 8.3$             NR                         NR                         Age, sex, smoking
  Lung: 94/347; uro-thelial: 117/347   69%                           Lung (medical records)                                                                                             $\geq 10.8$ vs. $< 10.8$                                      $\geq 12.5$ vs. $< 12.5$     $\geq 83.9$ vs. $< 83.9$                                                                                     
  $> 25\; y$                           Urothelial                    Urothelial                        Urothelial                                                                                                                                                                                                                                                                               
  Hospital                             0.3 (0.2, 0.5)                1.4 (0.9, 2.2)                    1.7 (1.1, 2.6)                                                                                                                                                                                                                                                                           
  Lung                                 Lung                          Lung                                                                                                                                                                                                                                                                                                                       
  1.1 (0.7, 1.8)                       2.3 (1.4, 3.8)                0.6 (0.4, 1.1)                                                                                                                                                                                                                                                                                                             
  [@c88]                               CC                            Córdoba, Argentina                Lung (medical records)                                                           Water (low-moderate)                                          $15.7 \pm 5.5$               $15.5 \pm 6.7$              $68.7 \pm 9.6$             NR                         NR                         Age, sex, smoking, drinking-water arsenic exposure
  45/75                                88%                                                             NR                                                                               $\geq 17.2$ vs. $< 11.8$                                      NR                                                                                                                                        
  20-80 y                              3.1 (1.1, 8.1)                                                                                                                                                                                                                                                                                                                                           
  Hospital                             $p - \text{trend} = 0.04$                                                                                                                                                                                                                                                                                                                                
  [@c41]                               CC 16/61                      Putai, Taiwan                     Non-melanoma skin (pathology)                                                    Water (artesian well $700–930\;\mu g/L$)                      $10.7 \pm 6.2$               $24.6 \pm 11.2$             $64.7 \pm 13.3$            $3.3 \pm 2.3$              $3.6 \pm 4.6$              Age, sex, $\beta - \text{carotene}$
  42%                                                                NR                                Among CAE $\leq 20\;{mg}/L - y$, $\leq 26.7$ vs. $> 26.7\%$:3.0 (0.3-27.8)       NR                                                            NR                           NR                                                                                                           
  $> 30\; y$                                                                                                                                                                                                                                                                                                                                                                                    
  General                                                                                                                                                                                                                                                                                                                                                                                       
  [@c113]                              CC 26/26                      Putai, Taiwan                     Non-melanoma skin[^*a*^](#t1n1){ref-type="table-fn"} (dermatologist diagnosis)   Urine (mean sum iAs, MMA, and DMA $56\;\mu g/L$)              12.3                         15.5                        72.2                       NR                         4.6                        Age, sex
  54%                                                                $> 2.3$ vs $\leq 2.3$             $> 15.5$ vs $\leq 15.5$                                                          $< 72.2$ vs $\geq 72.2$[^*b*^](#t1n2){ref-type="table-fn"}    $< 4.5$ vs. $\geq 4.5$                                                                                                                    
  Mean 63 y                            3.5 (0.7, 16.9)               5.5 (1.224.8)                     3.25 (1.1, 10.0)                                                                 3.3 (0.9, 12.1)[^*c*^](#t1n3){ref-type="table-fn"}                                                                                                                                                      
  Hospital                                                                                                                                                                                                                                                                                                                                                                                      
  [@c12]                               CC 76/224                     Tainan, Taiwan                    Non-melanoma skin (pathology)                                                    Urine (mean sum iAs, MMA, and DMA $44\;\mu g/L$)              $7.4 \pm 6.6$                $13.0 \pm 10.9$             $79.6 \pm 16.3$            $4.3 \pm 8.8$              $10.7 \pm 11.5$            Age, sex, education, smoking, alcohol, body mass index, sun exposure, CAE
  60%                                                                NR                                Highest vs. lowest tertile                                                       Highest vs. lowest tertile                                    $> 3$ vs. $\leq 1$           $> 9.4$ vs. $\leq 5$                                                                                         
  $> 30\; y$                           1.4 (0.6, 3.4)                0.8 (0.3, 1.9)                    1.3 (0.6, 2.9)                                                                   0.9 (0.4, 2.1)                                                                                                                                                                                          
  Hospital                             $p - \text{trend} > 0.05$     $p - \text{trend} > 0.05$         $p - \text{trend} > 0.05$                                                        $p - \text{trend} > 0.05$                                                                                                                                                                               
  [@c33]                               CC 323/319                    New Hampshire, USA                Squamous cell (pathology and medical records)                                    Urine (median sum iAs, MMA, and DMA $5.3\;\mu g/L$)           $\sim 6.3$ ± median          $\sim 9.5$ ± median         $\sim 78.4$ ± median       $\sim 1.5$ ± median        $\sim 8.3$ ± median        Age, sex, education, smoking, BMI, urine creatinine, skin reaction to sun exposure, water arsenic
  59%                                                                per 1% increase                   per 1% increase                                                                  per 1% increase-                                              per 1% increase              per 1% increase                                                                                              
  25--74 y                             1.00 (0.97, 1.04)             1.01 (0.97, 1.05)                 0.99 (0.97, 1.02)                                                                1.08 (0.95, 1.23)                                             1.00 (0.97, 1.03)                                                                                                                         
  General                                                                                                                                                                                                                                                                                                                                                                                       
  López-Carrillo et al. 2014           CC 1,016/1,028                Northern Mexico                   Breast cancer (pathology)                                                        Urine (geometric mean iAs conc. $18.4\;\mu g/g$ creatinine)   $10.2 \pm \text{median}$     $9.8 \pm \text{median}$     $79.7 \pm \text{median}$   $1.00 \pm \text{median}$   $8.00 \pm \text{median}$   Total inorganic arsenic, age, BMI, total breastfeeding, alcohol, smoking, age at first pregnancy, creatinine
  0%                                                                 $> 14.90$ vs. $\leq 6.55$         $> 13.3$ vs. $\leq 7.01$                                                         $> 84.96$ vs. $\leq 72.37$                                    $> 1.48$ vs. $\leq 0.65$     $> 11.73$ vs. $\leq 5.55$                                                                                    
  Mean 54 y                            0.90 (0.65, 1.24)             2.63 (1.89, 3.66)                 0.63 (0.45, 0.87)                                                                1.90 (1.39, 2.59)                                             0.42 (0.31, 0.59)                                                                                                                         

Note:Values shown as mean±SD, highest vs. lowest category, and eRR (95% CI), unless otherwise specified. BMI, body mass index, Ca, cancer; CAE, cumulative arsenic exposure; CC, case--control study; CI, confidence interval; CO, prospective cohort study; DMA, dimethylarsinate; eRR, estimated relative risk; iAs, inorganic arsenic; MMA, monomethylarsonate; NR, not reported; NS, not significant; PMI, primary methylation index (MMA/iAs); SD, standard deviation; SMI, secondary methylation index (DMA/MMA).

Skin cancer refers to non-melanoma skin cancer.

Lowest vs. highest categories.

Association for the DMA/MMA, rather than MMA/DMA.

### Urothelial cancer. {#s3.3.1}

Of five studies on urothelial cancer ([@c14]; [@c43]; [@c65]; [@c82]; [@c86]), four reported a positive association with MMA% ([@c43]; [@c65]; [@c82]; [@c86]), three with iAs% and DMA% ([@c43]; [@c65]; [@c82]), and three with PMI and SMI ([@c14]; [@c43]; [@c82]). For MMA%, the direction of the estimated relative risks for urothelial cancer comparing the highest to lowest category of MMA% was consistent for all studies (relative risks (RR) range from 1.2 to 2.8), although only one study association was statistically significant ([Table 1](#t1){ref-type="table"} and [Figure 3](#f3){ref-type="fig"}) ([@c82]). For SMI, the corresponding estimated relative risks were also consistent across studies (RR from 0.3 to 0.6), although only one study association was statistically significant ([@c82]). The corresponding estimated relative risks for iAs%, DMA% and PMI were inconsistent across studies and ranged from 0.3 to 1.4 for iAs%, from 0.3 to 1.7 for DMA%, and from 0.5 to 3.1 for PMI ([Table 1](#t1){ref-type="table"}).

![Summary of the associations of arsenic methylation patterns with cancer, cardiovascular disease, and diabetes-related outcomes based on the estimated relative risk (eRR) and 95% confidence interval (CI) shown in [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"}. Studies are sorted by estimated arsenic exposure (eAs) within each health outcome. The triangles indicate the direction of the association. An upward-pointing triangle stands for positive association while a downward-pointing triangle stands for a negative association. An upward-pointing triangle indicates a positive and statistically significant association (eRR above 1 and 95% CI not overlapping 1) and a lighter upward-pointing triangle indicates a positive but not statistically significant increase (eRR above 1 but 95% CI overlapping 1). A downward-pointing triangle indicates a negative and statistically significant association (eRR below 1 and 95% CI not overlapping 1) and a lighter downward-pointing triangle indicates a negative but not statistically significant association (eRR below 1 but 95% CI not overlapping 1). A horizontal arrow (↔) indicates a null association (eRR equal to 1). Gray open circles with no arrows indicate the data were not reported in the study. All the associations represented in this figure are also shown in [Tables 1](#t1){ref-type="table"}--[3](#t3){ref-type="table"} as eRR and 95% CI.](EHP577_f3){#f3}

### Lung cancer. {#s3.3.2}

Of the two studies on lung cancer ([@c65]; [@c88]), both reported an association with MMA% ([@c65]; [@c88]), and one also reported associations with iAs% and DMA% ([@c65]). No studies of lung cancer reported associations with PMI and SMI. For MMA%, the estimated relative risks comparing the highest to lowest category of MMA% were 2.3 and 3.1, both of them statistically significant ([Table 1](#t1){ref-type="table"}).

### Skin cancer. {#s3.3.3}

Of the four studies on skin cancer \[three nonmelanoma skin cancer ([@c12]; [@c41]; [@c113]), one squamous cell carcinoma ([@c33])\], four reported on the association with MMA% ([@c12]; [@c33]; [@c41]; [@c113]), two with iAs% ([@c33]; [@c113]), three with DMA% ([@c12]; [@c33]; [@c113]), two with PMI ([@c12]; [@c33]), and three with SMI ([@c12]; [@c33]; [@c113]). For MMA%, the estimated relative risks for skin cancer comparing the highest to lowest category of MMA% were consistent for all studies (RR range from 1.4 to 5.5), although only one study association was statistically significant ([@c113]). For iAs%, one study reported a null association and another showed a positive nonsignificant association ([Table 1](#t1){ref-type="table"}). For DMA%, one study found a positive significant association (RR of 3.25 ([@c113])) and the others found inverse but nonstatistically significant associations ([@c12]; [@c33]). For PMI, both studies showed positive but nonsignificant associations ([@c12]; [@c33]). For SMI, one study was nonsignificantly positive ([@c113]), one study was inverse but nonsignificant ([@c12]), and the other was null ([@c33]).

Arsenic Metabolism and Cardiovascular Disease {#s3.4}
---------------------------------------------

From 10 studies reporting cardiovascular outcomes, five were conducted in Taiwan ([@c46]; [@c44]; [@c104]; [@c112]), 2 in Bangladesh ([@c10], [@c11]), two in China ([@c55], [@c56]), one in the United States ([@c68]), and 1 in Mexico ([@c66]). All study populations were characterized by high arsenic exposure ($> 100\;\mu g/L$ in drinking water), except the study from the United States ([@c68]). Three were prospective cohort studies ([@c11]; [@c68]; [@c104]), one was a nested case--control study ([@c112]), and six were cross-sectional studies ([@c10]; [@c46]; [@c44]; [@c55], [@c56]; [@c66]). Study outcomes included hypertension ($n = 5$) ([@c46]; [@c55], [@c56]; [@c66]; [@c104]), carotid atherosclerosis ($n = 3$) ([@c10]; [@c44]; [@c112]), and overall cardiovascular disease ($n = 2$) ([@c11]; [@c68]). Five studies reported results for percentages of each metabolite (iAs%, MMA%, and DMA%) ([@c55], [@c56]; [@c68]; [@c104]; [@c112]), whereas the other five studies reported both percentages of each metabolite and methylation indices (PMI and SMI) ([Table 2](#t2){ref-type="table"}) ([@c10], [@c11]; [@c46]; [@c44]; [@c66]).

###### 

Studies of arsenic metabolism and cardiovascular diseases.

Table 2 lists the first author and year and the design cases/non case in the first and the second columns, respectively. The population characteristics and the outcomes are listed in the third and fourth columns, respectively. The arsenic exposure; the values of iAs%, MMA%, DMA%, PMI, SMI; and adjustment factors are listed in the other columns.

  Reference       Study design (case/noncase)                                                                         Men (%) Age range Source                                                                                                         Outcome (Ascertainment method)                                                                                                                          Arsenic exposure                                                                                                                       Adjustment factors                                                                                                                             
  --------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------- -------------------------- ------------------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  [@c68]          CO Total $n = 3,381$                                                                                Arizona, Oklahoma, North/South Dakota, USA                                                                                       CVD incidence and mortality (CHD, stroke and CHF; adjudicated by outcome assessment committee)                                                          Urine (median sum iAs, MMA, and DMA $9.7\;\mu g/g$ creatinine)                                                                         $8.9 \pm 5.0$                   $14.5 \pm 5.3$                  $76.6 \pm 8.6$             NR                        NR                        Age, sex, education, smoking, BMI, LDL cholesterol, study site, total inorganic arsenic
  45.0%                                                                                                               0.91 (0.84, 0.99) for incident CVD                                                                                               0.98 (0.90, 1.07) for incident CVD                                                                                                                      1.04 (0.96, 1.12) for incident CVD                                                                                                                                                                                                                                                    
  45--74 y        0.83 (0.73, 0.94) for fatal CVD                                                                     1.01 (0.87, 1.16) for fatal CVD                                                                                                  1.03 (0.91, 1.17) for fatal CVD                                                                                                                                                                                                                                                                                                                                                                                                               
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c11]          CCO 369/1,109 (subcohort)                                                                           Araihazar, Bangladesh                                                                                                            Fatal and nonfatal CVD (CHD and stroke; medical records, death certificate, outcome assessment committee)                                               Urine (mean sum iAs, MMA, and DMA $273\;\mu g/g$ creatinine)                                                                           $15.5 \pm 6.9$                  $13.2 \pm 5.2$                  $71.3 \pm 8.7$             $1.0 \pm 0.8$             $6.0 \pm 3.1$             Age, sex, education, smoking, hypertension, diabetes
  51%                                                                                                                 (17.4, 69.3) vs. (0.3, 12.4)                                                                                                     (14.4, 33.8) vs. (0.2, 10.3)                                                                                                                            (75.6, 99.2) vs. (27.9, 68.6)                                                                                                          (1.06, 19.57) vs (0.01, 0.66)   (7.2, 32.3) vs. (1.4, 4.8)                                                                                     
  $\geq 18\; y$   1.1 (0.7, 1.6)                                                                                      1.6 (1.1, 2.2)                                                                                                                   0.8 (0.5, 1.1)                                                                                                                                          0.9 (0.6, 1.3)                                                                                                                         0.5 (0.3, 0.9)                                                                                                                                 
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c112]         NCC 163/163                                                                                         Ilan, Taiwan                                                                                                                     Carotid atherosclerosis ($\text{IMT} \geq 1.0\;{mm}$ or the presence of ECCA plaque)                                                                    Water ($< 0.15 \sim 3,590\;\mu g/L$)                                                                                                   NR                              NR                              NR                         NR                        NR                        Age, sex, smoking, total cholesterol, hypertension, CAE
  47%                                                                                                                 $\geq 13.4$ vs. $< 13.4$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  $\geq 40\; y$   0.5 (0.1, 2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c44]          CS 121/183                                                                                          Putai, Taiwan                                                                                                                    Carotid atherosclerosis ($\text{IMT} \geq 1.0{mm}$ or the presence of ECCA plaque)                                                                      Urine (mean sum iAs, MMA, and DMA $82\;\mu g/L$)                                                                                       7.2 ±7.2                        $13.9 \pm 8.9$                  $78.9 \pm 11.9$            $3.3 \pm 5.3$             $13.3 \pm 47.9$           Age, sex, smoking, hypertension, diabetes, total cholesterol, total urine arsenic
  52%                                                                                                                 Case (6.9) vs. control (7.4)                                                                                                     Case (15.1) vs. control (13.1)                                                                                                                          Case (78.1) vs. control (79.5)                                                                                                         Case (3.9) vs. control (2.9)    Case (9.1) vs. control (16.0)                                                                                  
  $\geq 30\; y$   $p = 0.19$                                                                                          $p = 0.11$                                                                                                                       $p = 0.08$                                                                                                                                              $p = 0.78$                                                                                                                             $p = 0.10$                                                                                                                                     
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c10]          CS Total $n = 959$                                                                                  Araihazar, Bangladesh                                                                                                            Carotid IMT                                                                                                                                             Urine (mean sum iAs, MMA, and DMA $260\;\mu g/g$ creatinine)                                                                           15.5                            13.0                            71.6                       0.98                      6.7                       Age, sex, education, smoking, body mass index, systolic blood pressure, diabetes
  40%                                                                                                                 Per 10% change:                                                                                                                  Per 10% change                                                                                                                                          Per 10% change                                                                                                                         Per 1-unit change               Per 1-unit change                                                                                              
  $\geq 18\; y$   4.1 ($- 4.1$, 12.3)                                                                                 12.1 (0.4-23.8)                                                                                                                  $- 6.3$ ($- 12.8$, 0.2)                                                                                                                                 1.5 ($- 5.2$ , 8.1)                                                                                                                    $- 1.2$ ($- 2.8$, 0.4)                                                                                                                         
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c46]          CS 372/499                                                                                          Putai, Taiwan                                                                                                                    HTN                                                                                                                                                     Urine (mean sum iAs, MMA, and DMA $77\;\mu g/L$)                                                                                       $8.2 \pm 7.6$                   $13.6 \pm 8.7$                  $78.1 \pm 12.2$            $3.1 \pm 8.0$             $11.6 \pm 31.0$           Age, sex, smoking, alcohol, body mass index, triglyceride, CAE
  44%             (History and/or a $\text{SBP} \geq 160\,\text{mmHg}$ or a $\text{DBP} \geq 90\,\text{mmHg}$)                                                                                                                                         $\geq 8.0$ vs. $< 4.5$                                                                                                                                  $\geq 15.5$ vs. $< 8.1$                                                                                                                $\geq 85.3$ vs. $< 75.8$        $\geq 2.7$ vs. $< 1.2$          $\geq 9.8$ vs. $< 4.9$                                                         
  $\geq 30\; y$   $- 1.2$ (0.8-1.9)                                                                                   1.0 (0.7, 1.6)                                                                                                                   1.1 (0.7, 1.6)                                                                                                                                          0.9 (0.6, 1.3)                                                                                                                         1.1 (0.7, 1.7)                                                                                                                                 
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c104]         CO 110/242                                                                                          Putai, Taiwan                                                                                                                    HTN                                                                                                                                                     Water (mean CAE $12\;{mg}/L - y$)                                                                                                      NR                              NR                              NR                         NR                        NR                        Age, sex, body mass index, glucose
  46%             ($\text{SBP} \geq 140\,\text{mmHg}$, a $\text{DBP} \geq 90\,\text{mmHg}$, or anti-HTN medication)                                                                                                                                    $> 17$ vs. $< 10$                                                                                                                                       $> 12$ vs. $< 6$                                                                                                                       $> 0.81$ vs. $< 0.71$                                                                                                                          
  $\geq 30\; y$   0.7 (0.3, 1.6)                                                                                      0.6 (0.3, 1.3)                                                                                                                   1.4 (0.6, 3.2)                                                                                                                                                                                                                                                                                                                                                                                                                                
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c55]          CS 182/487                                                                                          Inner Mongolia, China                                                                                                            HTN ($\text{SBP} \geq 140\,\text{mmHg}$ or $\text{DBP} \geq 90\,\text{mmHg}$ or anti-HTN medication)                                                    Water (geometric mean CAE $0.02–2.9{mg}/L - y$)                                                                                        9.2                             13.3                            70.2                       NR                        NR                        Age, sex, smoking, alcohol, body mass index, diabetes
  43%                                                                                                                 Per % change within water arsenic ($\mu g/L$) categories $< 10$ : 0.8 (0.3, 2.3) 10--50: 1.5 (0.6, 3.9) $> 50$: 2.0 (1.0, 4.1)   Per % change within water arsenic ($\mu g/L$) categories $< 10$ or anti-HTN medication): 0.5 (0.05, 4.5)10--50: 0.8 (0.1, 7.1) $> 50$: 1.8 (0.4, 7.9)   Per % change within water arsenic ($\mu g/L$ ) categories $< 10$ : 0.8 (0.1, 6.9) 10--50: 0.1 (0.002, 4.4) $> 50$: 0.04 (0.002, 0.8)                                                                                                                                                  
  Mean 50 y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  General                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  [@c56]          CS 168/436                                                                                          Shanxi, China                                                                                                                    HTN ($\text{SBP} \geq 140\,\text{mmHg}$ or $\text{DBP} \geq 90\,\text{mmHg}$ or anti-HTN medication)                                                    Urine (geometric mean sum iAs, MMA, and DMA $136–179\mu g/g$ creatinine)                                                               9.5                             12.9                            69.5                       NR                        NR                        Age, sex, smoking, alcohol, body mass index
  42%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  -Mean 49 y      $> 15.8$ vs. $< 7.3$                                                                                $> 16.4$ vs. $< 11.9$                                                                                                            $> 79.1$ vs. $< 68.7$                                                                                                                                                                                                                                                                                                                                                                                                                         
  General         1.5 (0.9, 2.5)                                                                                      1.00 (0.6, 1.7)                                                                                                                  0.7 (0.4, 1.2)                                                                                                                                                                                                                                                                                                                                                                                                                                
  [@c66]          CS Total $n = 1,038$                                                                                Chihuahua, Mexico                                                                                                                HTN ($\text{SBP} \geq 140\,\text{mmHg}$ or $\text{DBP} \geq 90\,\text{mmHg}$ or anti-HTN medication)                                                    Urine (median total inorganic As 55.8 ($\mu g/L$))                                                                                     $8.9 \pm \text{Median}$         $14.0 \pm \text{Median}$        $76.8 \pm \text{Median}$   $1.6 \pm \text{Median}$   $5.5 \pm \text{Median}$   Total inorganic arsenic, age, sex, education, ethnicity, weight, waist circumference, smoking, alcohol, seafood intake, water source
  31.4%                                                                                                               $\geq 12.3$ vs. $< 6.4$                                                                                                          $\geq 17.7$ vs. $< 10.9$                                                                                                                                $\geq 81.5$ vs. $< 70.7$                                                                                                               $\geq 2.1$ vs. $< 1.2$          $\geq 7.4$ vs. $< 4.1$                                                                                         
  Mean 46 y       $\sim 0.8$                                                                                          $\sim 0.5$                                                                                                                       $\sim 1.8$                                                                                                                                              $\sim 1.2$                                                                                                                             $\sim 1.9$                                                                                                                                     
  General         ($p - \text{value} > 0.05$)                                                                         ($p - \text{value} < 0.05$)                                                                                                      ($p - \text{value} < 0.05$)                                                                                                                             ($p - \text{value} > 0.05$)                                                                                                            ($p - \text{value} < 0.05$)                                                                                                                    

Note: Values shown as mean±SD, highest vs. lowest category, and eRR (95% CI), unless otherwise specified. CAE, cumulative arsenic exposure; CCO, case-cohort study; CHF, congestive heart failure; CI, confidence interval; CO, prospective cohort study; CS, cross-sectional study; CVD, cardiovascular disease; DBP, diastolic blood pressure; DMA, dimethylarsinate; ECCA, extra-cranial carotid artery; eRR, estimated r4elative risk; HTN, hypertension; iAs, inorganic arsenic; IMT, intimal-medial thickness; MMA, monomethylarsonate; NCC, nested case--control study; NR, not reported; PMI, primary methylation index (MMA/iAs); SBP, systolic blood pressure; SD, standard deviation; SMI, secondary methylation index (DMA/MMA).

###### 

Studies of arsenic metabolism and metabolic syndrome and diabetes.

Table 3 lists the first author and year and the design cases/non case in the first and the second columns, respectively. The population characteristics and the outcomes are listed in the third and fourth columns, respectively. The arsenic exposure; the values of iAs%, MMA%, DMA%, PMI, SMI; and adjustment factors are listed in the other columns.

  Reference         Study design (case/noncase)   Men (%) Age range Source                     Outcome (Ascertainment method)                                                                                                     Arsenic exposure                                                Adjustment factors                                                                                                                         
  ----------------- ----------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------- ----------------------------- -------------------------- ------------------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  [@c9]             CS 111/136                    Putai, Taiwan                                Metabolic Syndrome ($\geq 3$ Adult Treatment Panel III Criteria)                                                                   Urine (mean sum iAs, MMA, and DMA $44\;\mu g/g$ creatinine)     $17.0 \pm 15.4$               $10.1 \pm 9.0$                $72.8 \pm 19.1$            $0.8 \pm 0.7$             $17.9 \pm 32.0$           Age, betel nut chewing
  43%                                             NR                                           $> 11.3$ vs. $< 5.8$                                                                                                               $> 81.9$ vs. $< 72.4$                                           $> 0.9$ vs. $< 0.4$           $> 12.0$ vs. $< 6.1$                                                                                         
  $\geq 40\; y$     0.4 (0.2, 0.7)                2.0 (1.1, 3.9)                               0.4 (0.2, 0.8)                                                                                                                     2.6 (1.4, 5.1)                                                                                                                                                                                             
  General                                                                                                                                                                                                                                                                                                                                                                                                                                    
  [@c23]            CS 25/233                     Zimapán and Lagunera, Mexico                 Diabetes ($\text{FBG} \geq 126\;{mg}/\text{dL}$, $\text{OGTT} \geq 200\;{mg}/\text{dL}$, self-reported diagnosis, or medication)   Urine (mean sum iAs, MMA, and DMA $43\;\mu g/L$)                NR                            NR                            NR                         1.3                       5.6                       Age, sex, obesity, hypertension
  33%                                             per IQR change                               per IQR change                                                                                                                                                                                                                                                                                                                                
  Mean 34 y         1.0 (0.9, 1.1)                1.4 (0.9, 2.1)                                                                                                                                                                                                                                                                                                                                                                             
  General                                                                                                                                                                                                                                                                                                                                                                                                                                    
  [@c75]            CC 140/180                    Faridpur, Bangladesh                         Diabetes (self-reported diagnosis and $\text{HbA}1c \geq 7\%$, confirmed by medical records)                                       Urine (mean sum iAs, MMA, and DMA $243\;\mu g/L$)               9.6                           9.4                           80.1                       1.3                       10.0                      Age, sex, location, smoking, body mass index, family history of diabetes, income, duration of drinking water, water arsenic
  43%                                             DM (8.6) vs. non-DM (10.4)                   DM (8.8) vs. non-DM (9.7)                                                                                                          DM (82.6) vs. non-DM (79.9)                                     DM (1.4) vs. non-DM (1.2)     DM (11.6) vs. non-DM (10.0)                                                                                  
  $\geq 20\; y$     $p = 0.35$                    $p = 0.08$                                   $p = 0.14$                                                                                                                         $p = 0.37$                                                      $p = 0.09$                                                                                                                                 
  General                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Kuo et al. 2015   CO 396/1,298                  Arizona, Oklahoma, North/South Dakota, USA   Diabetes ($\text{FBG} \geq 126\;{mg}/\text{dL}$, $2\text{HPG} \geq 200\;{mg}/\text{dL}$, self-reported diagnosis, or medication)   Urine (mean sum iAs, MMA, and DMA $11.7\;\mu g/g$ creatinine)   9.2                           15.6                          75.2                       NR                        NR                        Age, sex, education, smoking, alcohol, BMI, waist-to-hip ratio, study sites, total inorganic arsenic
  45.0%                                           per 5% change                                per 5% change                                                                                                                      per 5% change                                                                                                                                                                                              
  45--74 y          1.0 (0.89, 1.12)              0.84 (0.76, 0.94)                            1.07 (1.00, 1.15)                                                                                                                                                                                                                                                                                                                             
  General                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Mendez 2016       CS Total $n = 1,038$          Chihuahua, Mexico                            Diabetes ($\text{FBG} \geq 126\;{mg}/\text{dL}$, $2\text{HPG} \geq 200\;{mg}/\text{dL}$, self-reported diagnosis, or medication)   Urine (median total inorganic As 55.8 ($\mu g/L$))              $8.9 \pm \text{Median}$       $14.0 \pm \text{Median}$      $76.8 \pm \text{Median}$   $1.6 \pm \text{Median}$   $5.5 \pm \text{Median}$   Total inorganic arsenic, age, sex, education, ethnicity, weight, waist circumference, smoking, alcohol, seafood intake, water source
  31.4%                                           $\geq 12.3$ vs. $< 6.4$                      $\geq 17.7$ vs. $< 10.9$                                                                                                           $\geq 81.5$ vs. $< 70.7$                                        $\geq 2.1$ vs. $< 1.2$        $\geq 7.4$ vs. $< 4.1$                                                                                       
  Mean 46 y         $\sim 0.6$                    $\sim 0.3$                                   $\sim 3.1$                                                                                                                         $\sim 0.4$                                                      $\sim 4.9$                                                                                                                                 
  General           ($p - \text{value} > 0.05$)   ($p - \text{value} < 0.05$)                  ($p - \text{value} < 0.05$)                                                                                                        ($p - \text{value} < 0.05$)                                     ($p - \text{value} < 0.05$)                                                                                                                

Note: Values shown as mean±SD, highest vs. lowest category, and eRR (95% CI), unless otherwise specified. ATPIII, National Cholesterol Education Program\'s Adult Treatment Panel III report; BMI, Body mass index (${{kg}/m}^{2}$); CC, case--control study; CI, confidence interval; CS, cross-sectional study; DM, diabetes mellitus; DMA, dimethylarsinate; eRR, estimated relative risk; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; 2HPG, 2-h postprandial glucose; iAs, inorganic arsenic; IMT, intimal-medial thickness; MMA, monomethylarsonate; NR, not reported; OGTT, oral glucose tolerance test; PMI, primary methylation index (MMA/iAs); SD, standard deviation; SMI, secondary methylation index (DMA/MMA).

### Cardiovascular disease incidence and mortality. {#s3.4.4}

Clinical cardiovascular disease was defined as the occurrence of fatal and nonfatal stroke, coronary heart disease, heart failure, or other heart disease during the follow-up ([@c11]; [@c68]). Two prospective cohort studies, one from Bangladesh and one from the United States, investigated the association between arsenic metabolism and incident cardiovascular disease based on MMA% ([Table 2](#t2){ref-type="table"}) ([@c11]; [@c68]). The U.S. cohort ([@c68]) also investigated the association of arsenic metabolism with cardiovascular disease mortality. The Bangladesh cohort also reported iAs%, DMA%, PMI, and SMI. Higher MMA% and lower SMI were associated with higher risk of incident cardiovascular disease in Bangladesh, whereas the association for iAs%, DMA%, and PMI were around the null and nonsignificant ([@c11]). In the U.S. cohort, lower iAs% was associated with increased risk of clinical cardiovascular incidence and mortality ([@c68]).

### Carotid atherosclerosis. {#s3.4.5}

The evaluation of carotid atherosclerosis was based on extracranial carotid Doppler ultrasound ([@c10]; [@c44]; [@c112]). Of the three studies on carotid atherosclerosis, one was prospective ([@c112]) and two were cross-sectional. All reported the association with MMA% ([@c10]; [@c44]; [@c112]), two with iAs% and DMA% ([@c10]; [@c44]), and two with PMI and SMI ([@c10]; [@c44]) ([Table 2](#t2){ref-type="table"}). Two studies found higher levels of carotid intima-media with higher MMA%, although only one was statistically significant ([@c10]; [@c44]). For iAs%, the two studies showed inconsistent results ([@c10]; [@c44]). For DMA%, the results were consistently but nonsignificantly inverse for higher DMA% and reduced risk of carotid atherosclerosis ([@c10]; [@c44]). For PMI and SMI, the findings were consistently null for both studies.

### Hypertension. {#s3.4.6}

All studies on hypertension followed the World Health Organization standard protocol to measure blood pressure and define hypertension ([@c46]; [@c55], [@c56]; [@c66]; [@c104]). Four studies were cross-sectional and one was a prospective cohort study ([@c104]). All reported the association with iAs%, MMA%, and DMA%, and two also reported on the association with PMI and SMI ([@c46]; [@c66]). The association between MMA% and hypertension was inconsistent across studies, with studies finding positive ([@c55]), inverse ([@c66]; [@c104]) and null associations ([@c46]; [@c56]), none of them statistically significant. The associations with iAs% and DMA% were also inconsistent ([Table 2](#t2){ref-type="table"} and [Figure 3](#f3){ref-type="fig"}).

Arsenic Metabolism and Diabetes-Related Outcomes {#s3.5}
------------------------------------------------

Five studies evaluated the associations of arsenic metabolism with diabetes-related outcomes ([@c9]; [@c23]; [@c51]; [@c66]; [@c75]). All studies were published after 2011. Three studies were cross-sectional ([@c9]; [@c23]; [@c66]), one was case--control ([@c75]), and one was a prospective cohort ([@c51]). The studies were conducted in populations from Taiwan ([@c9]), Bangladesh ([@c75]), Mexico ([@c23]; [@c66]), and the United States ([@c51]). Most populations were exposed to high arsenic levels ($> 100\mu g/L$ in drinking water) except in a study from the United States ([@c51]). The study outcomes included diabetes ($n = 4$) ([@c23]; [@c51]; [@c66]; [@c75]) and metabolic syndrome ($n = 1$) ([@c9]). The definitions of diabetes were consistent across studies using information on glycemia together with self-reported physician diagnosis or medication history ([@c23]; [@c51]; [@c66]; [@c75]). Of the five studies, four reported the association with MMA%, iAs%, DMA% ([@c9]; [@c51]; [@c66]; [@c75]), and four on the PMI and SMI ([@c9]; [@c23]; [@c66]; [@c75]). Four studies found that lower levels of MMA% and higher levels of DMA% were associated with higher risk of diabetes or metabolic syndrome ([@c9]; [@c51]; [@c66]; [@c75]). The SMI was positively associated with higher risk of diabetes ([@c9]; [@c23]; [@c66]; [@c75]), although the association was significant only in two studies ([@c9]; [@c66]). For PMI, the association with diabetes or metabolic syndrome was nonsignificantly positive in one study ([@c75]), significantly inverse in two studies ([@c9]; [@c66]), and null in one study ([@c23]).

Discussion {#s4}
==========

Main Findings {#s4.1}
-------------

This systematic review of arsenic metabolism and disease found that the association with arsenic metabolism patterns was different across different chronic disease outcomes ([Figure 3](#f3){ref-type="fig"}). For cancer, most studies found an association between cancer outcomes with higher MMA% and lower DMA%. For cardiovascular disease, most studies found that higher MMA% was associated with incident cardiovascular diseases and prevalent carotid atherosclerosis, although most of them were not statistically significant. For hypertension, no studies found any association with arsenic metabolism. For diabetes, lower MMA% and higher DMA% was associated with higher risk of diabetes or the metabolic syndrome in all studies. A major limitation in this area of research is the heterogeneity in the methods used for modeling arsenic metabolism and the selective reporting, which makes the comparison and interpretation of the results challenging. The research community should reach consensus on the appropriate methods for evaluating arsenic metabolism in epidemiologic studies.

In the evaluation of arsenic metabolism across populations, we found substantial interpopulation variability in the distribution of the arsenic metabolism measures. Interpopulation variability of arsenic metabolism has been recognized in previous studies ([@c59]; [@c96]). In the current review, we found that arsenic exposure (measured in drinking water or urine) was related to iAs% and DMA% (high arsenic in water being associated with higher iAs% and lower DMA%); however, there was a less pronounced association with MMA%. By comparing all the data on MMA% from multiple countries side by side, we also observed that the variability for MMA% across diverse populations was lower than variability of iAs% and DMA%. To our knowledge, few studies have directly investigated the association between arsenic exposure levels and arsenic metabolism. A similar pattern was also observed in the region of Lagunera in Mexico, although the sample size was small ([@c24]). Lower variability in MMA% in human populations is also consistent with an animal study in mice showing that an increase in sodium arsenate from 0.5 to $5,000\;\mu g/{kg}$ increased iAs% by 14.4% and decreased DMA% by 16.1% but only increased MMA% by 1.3% ([@c48]). In Southwestern Taiwan, a $17.8 - \mu g/L$ reduction in mean sum of inorganic arsenic exposure (baseline $74.9\;\mu g/L$ to $57.1\;\mu g/L$) over 15 y of follow-up was associated with a 4.9% decrease in iAs%, a 6.8% decrease in MMA%, and an 11.7% increase in DMA%, although this observation did not account for survival bias ([@c44]). Future research is needed to understand how arsenic metabolism capacity responds to environmental arsenic exposure.

Beyond arsenic exposure levels, genetic polymorphisms, particularly in the arsenic (III) methyltransferase (AS3MT) gene, have been considered major determinants in interindividual variability of the arsenic methylation patterns ([@c1]; [@c29]). Age, sex, and body mass index may be other major determinants of arsenic metabolism ([@c50]). Epidemiological studies of arsenic metabolism and disease need to carefully consider for which factors to adjust. At a minimum, all studies of arsenic metabolism should adjust for arsenic exposure levels, in order to assess the health effects beyond what could be related to differences in arsenic exposure. Adjustment for age and sex should also be required. In addition to age and sex, body mass index, nutritional status, and genetic variants are other major determinants of arsenic metabolism. For instance, the large variation in arsenic metabolism profile observed in the two study populations with comparable age and arsenic exposure level in Bangladesh could potentially be explained by differences in nutritional status as reflected in urine creatinine level ($178.5\;{mg}/\text{dL}$ in Faridpur vs. $59.7\;{mg}/\text{dL}$ in Araihazar). If possible, epidemiologic studies should also evaluate potential effect modification between arsenic exposure levels and arsenic metabolism. In the current systematic review, due to the limited number of studies for each endpoint, unfortunately we could not evaluate the joint effect between arsenic exposure and metabolism in disease development. As the number of studies evaluating arsenic exposure and metabolism in disease development increases, meta-regression techniques could contribute to that understanding.

Implications for Public Health {#s4.2}
------------------------------

The importance of evaluating the role of arsenic metabolism in explaining interindividual differences in arsenic-related disease was recognized in the late 1990s, with the first study on the higher risk of nonmelanoma skin cancer with higher MMA% in Southwestern Taiwan being published in 1997 ([@c41]). With advances in analytical technology, including sensitive methods to detect the relevant arsenic species in the urine, and the recognition of the importance of understanding the role of arsenic metabolism for the evaluation of susceptibility in risk assessment, the number of epidemiologic studies evaluating the association between arsenic metabolism and health effects has grown. Initially, the studies pointed at a higher risk of disease being associated with higher MMA%. This finding was consistent with the detoxification interpretation of methylation and the need to fully methylate inorganic arsenic to DMA to minimize arsenic health effects. A slower second methylation could result in higher concentrations of trivalent MMA (MMA^III^) in human tissues. In cytotoxicity studies, MMA^III^ has shown to be as toxic or more than arsenite ([@c81]). Most epidemiologic studies cannot measure MMA^III^ in urine, as it is a very unstable compound that quickly revert to pentavalent MMA. In a small study in central Mexico, participants with skin lesions had higher levels of MMA^III^, despite similar total urine arsenic ([@c99]). Recent studies on diabetes-related outcomes, however, have shown that the association of arsenic metabolism patterns with health outcomes can be more complex than originally thought and suggest that faster methylation or more complete methylation could also increase the risk of diabetes. A similar association has also been found between higher DMA% and obesity and increased body mass index ([@c34]; [@c35]; [@c93]). From a mechanistic perspective, experimental evidence from animal studies has shown that methylation could be a bioactive process with DMA (III) being a highly toxic dimethylated arsenic species targeting murine pancreatic islet cells ([@c27]; [@c63]; [@c64]). Other indirect lines of evidence suggest that the synthesis and regulation of the main methyl donor for arsenic methylation, *S*-adenosylmethionine (SAM) generated through the one-carbon metabolism, may be critical for glucose and lipid homeostasis ([@c49]; [@c58]; [@c72]; [@c98]; [@c103]). These complex findings imply that manipulating individuals' arsenic metabolism profile toward complete methylation via nutritional modification, for instance, through supplementation with folate ([@c32]; [@c39]), may be more challenging than anticipated if increasing DMA% is related to a higher risk of diabetes-related metabolic complications. Additional long-term prospective epidemiological research and experimental research is needed to confirm and understand the role of arsenic metabolism and its connections with arsenic exposure, relevant exposure windows, genetics, nutrition, co-infections, and the microbiome ([@c8]; [@c62]).

Limitations of Current Research {#s4.3}
-------------------------------

A major limitation in comparing studies, however, is the heterogeneity in the description and analysis of arsenic metabolism. For instance, when percentages of the species relative to their sum are presented, many studies only show the results for one of the species ([@c41]; [@c88]; [@c112]). Similarly, only one of the two methylation indices are often presented. In addition to the selective reporting, the modeling methods used have generally failed to recognize that the three species (inorganic arsenic, MMA, and DMA) are interrelated and sum to 100%. Using conventional statistical methods designed for inherently compositional data may lead to inappropriate inferences ([@c3]; [@c78]). In the 1980s, John Aitchison introduced compositional data analysis to address this common issue in geoscience ([@c2], [@c3]). However, this technique is not widely recognized even in the area of geochemical research ([@c6]). Only recently, methods such as the leave-one-out approach or the use of triplots to represent the simultaneous distribution of arsenic metabolism have been used by environmental scientists ([@c35]; [@c51]).

The present findings should be interpreted cautiously. First, the possibility of publication bias cannot be ignored as null associations may be less likely to be published. Publication bias may overestimate the consistency of the relationship between arsenic metabolism and the selected health outcomes. Second, as most studies were cross-sectional or case--control designs, the possibility of reverse causation cannot be excluded. Also, adjustment for confounding was limited in some studies and overall we cannot exclude the possibility of residual confounding. However, the consistency of the findings adds support to conducting additional research to further assess the causality of these associations and a more comprehensive risk assessment targeting arsenic metabolism. Third, for the association between arsenic metabolism biomarkers and arsenic exposure we combined data across studies at different time periods, in different laboratories, and with different genetic background and nutritional status. Fourth, to obtain a fully comprehensive picture of the interplay between arsenic exposure and arsenic metabolism biomarkers, future reviews should expand to include all studies evaluating both arsenic exposure and metabolism. Fifth, in this review, we focused on the role of current arsenic exposure in arsenic metabolism rather than past exposure. Future research efforts should also be aimed to identify an appropriate population with both past and current arsenic exposure data to evaluate the effect of past arsenic exposure on the evolution of arsenic metabolism. Lastly, in this review, we focused on the role of current arsenic exposure in arsenic metabolism rather than past exposure. Future research efforts should identify a population with both past and current arsenic exposure data and longitudinal follow-up to evaluate the effect of past arsenic exposure on changes in arsenic metabolism.

Opportunities and Challenges for Future Studies {#s4.4}
-----------------------------------------------

Future studies with large sample size, appropriate baseline and prospective arsenic metabolism estimation, and sufficient long-term follow-up will help verify the independent association between arsenic metabolism and various health effects, and the interaction between arsenic exposure and metabolism on the development of chronic diseases. Developing a simple and interpretable modeling approach for arsenic metabolism is a research priority, although it might be difficult due to population specific complexities and the contribution of unmeasured covariates such as diet and genetic determinants. For example, interpretation of ratio measures of methylation (both PMI and SMI) is challenging, despite their previous popularity in epidemiological studies ([@c24]). It is difficult to predict whether changes in the numerator or the denominator will have a dominant effect, and thus associations with a methylation index obscures whether the association lies with the numerator or the denominator.

The biological meaning of arsenic metabolism may extend beyond increasing risks of arsenic toxicity. Arsenic metabolism may be an integrated marker reflecting genetic variations on arsenic sensitivity and long-term environmental arsenic exposure on genetic modification ([@c29]). Arsenic metabolism may also reflect differential microbiome distribution across humans and human populations, as it has been shown that gut microorganisms can methylate inorganic arsenic ([@c26]). Arsenic metabolism is also related to one-carbon nutrients as demonstrated in clinical trials from Bangladesh ([@c31]; [@c80]). The interplay between one-carbon metabolism, arsenic metabolism, and DNA methylation provides an opportunity to explore the genomic coding, metabolism regulation, and phenotype expression from a mechanistic perspective ([@c5]). One-carbon metabolism is composed of three key cycles including the methionine cycle, the folate cycle, and the cysteine-cystathionine cycle ([@c58]; [@c89]). The major methyl donor in humans, *S*-adenosylmethionine, is generated through the methionine cycle and facilitates more than 50 methylation reactions, including DNA methylation and arsenic methylation ([@c1]; [@c85]). The methionine cycle is completed by the re-methylation of homocysteine back to methionine, through the folate cycle ([@c90]), or by irreversibly degrading homocysteine into cysteine ([@c106]). Dysfunction of the methionine cycle has been linked to chronic diseases including cancer and cardiovascular disease ([@c5]; [@c58]). The cysteine--cystathionine cycle involves glutathione-transsulfuration and generates antioxidant thio buffers, which are critical to maintaining intracellular reduction--oxidation status ([@c25]). The imbalance of redox status has also been linked to cancer metabolism ([@c7]; [@c69]), cardiovascular disease ([@c114]), and diabetes ([@c28]). Indeed, increasing epidemiological evidence supports the association between arsenic exposure and global DNA methylation status ([@c73]; [@c83]). Moreover, mathematical modeling to approach the complexity of one-carbon metabolism and the interaction between the one-carbon and arsenic metabolism has been initiated ([@c53]; [@c74]).

Conclusions {#s5}
===========

This is the first systematic review evaluating the association between arsenic metabolism and several chronic disease outcomes. Specific methylation patterns were associated with increased disease risk, in different directions for different diseases. Cancer and cardiovascular disease outcomes were related to higher MMA%, whereas diabetes and the metabolic syndrome were in general related to lower MMA% and higher DMA%. Our analysis scope and conclusions were constrained due to small sample size, limited prospective evidence, and inconsistent arsenic metabolism reporting and statistical approach across studies. These findings call for a consensus on reporting standards for the evaluation of the health effects of arsenic metabolism. Conducting large prospective cohort studies in populations exposed to a wide range of arsenic exposure levels is critical to better characterize the interplay of arsenic metabolism with factors that influence the individual metabolism patterns, including arsenic exposure levels and genetic determinants of arsenic metabolism. Understanding the biological and epidemiological meaning of arsenic metabolism could improve the risk assessment of arsenic toxicity and provide a potential tool for disease prediction, prevention, and control.
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